MDA-19 is a drug that acts as a potent and selective agonist for the cannabinoid receptor CB2, with reasonable selectivity over the psychoactive CB1 receptor, though with some variation between species. In animal studies it was effective for the treatment of neuropathic pain, but failed to produce cannabis-like behavioural effects.
IUPAC name: (3Z)-N’-(1-hexyl-2-oxoindolin-3-ylidene)benzohydrazide
CAS number: 1048973-47-2
Purity: 99,9% min
Appearance: white powder